Sign In
26 May 2023 07:00
Ā
Ā
Ā
Destiny Pharma plc
Ā
("Destiny Pharma" or the "Company")
Ā
Director Dealing
Ā
Ā
Brighton, United KingdomĀ - 26 May 2023Ā - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that on 25 May 2023, certain Directors of the Company have purchased ordinary shares (the "Purchases") of 1 pence each in the Company ("Ordinary Shares"). Full details of the Purchases are detailed in the table below.
Director | Position | Ordinary Shares Purchased | Purchase Price | Resultant Holding | % of total voting rights |
Nick Rodgers | Chairman | 14,780 49,477 | 30.35 pence 31 pence | 218,901 | 0.23% |
Debra Barker | Interim Chief Executive Officer | 20,000 | 33 pence | 88,461 | 0.09% |
Aled Williams | Non-Executive Director | 50,000 | 31 pence | 50,000 | 0.05% |
Ā
Ā
For further information, please contact:Ā
Ā
Destiny Pharma plcĀ
Dr Debra Barker, CEO
Shaun Claydon, CFOĀ
+44 (0)1273 704 440Ā
pressoffice@destinypharma.comĀ
Ā
finnCap LtdĀ (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Ā
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Ā
Optimum Strategic CommunicationsĀ
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.comĀ
Ā
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Ā
Ā
Ā
Ā
About Destiny Pharma
Ā
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
Ā
For further information on the Company, please visitĀ https://www.destinypharma.com
Ā
Ā
Ā
Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.
Ā
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Nick Rodgers | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Chairman | ||||
b) | Initial notification/Amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Destiny Pharma plc | ||||
b) | LEI | 213800O9WH9Z38EHAC95 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each in Destiny Pharma Plc | ||||
Identification code | GB00BDHSP575 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: Ā· Aggregated volume Ā· Price | Ā See 4c) above | ||||
e) | Date of the transaction | 25 May 2023 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Ā
Ā
Ā
5. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Debra Barker | ||||
6. | Reason for the Notification | |||||
a) | Position/status | Interim Chief Executive Officer | ||||
b) | Initial notification/Amendment | Initial Notification | ||||
7. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Destiny Pharma plc | ||||
b) | LEI | 213800O9WH9Z38EHAC95 | ||||
8. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each in Destiny Pharma Plc | ||||
Identification code | GB00BDHSP575 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: Ā· Aggregated volume Ā· Price | Ā See 4c) above | ||||
e) | Date of the transaction | 25 May 2023 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Ā
Ā
9. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Aled Williams | ||||
10. | Reason for the Notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification/Amendment | Initial Notification | ||||
11.Ā | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Destiny Pharma plc | ||||
b) | LEI | 213800O9WH9Z38EHAC95 | ||||
12.Ā | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each in Destiny Pharma Plc | ||||
Identification code | GB00BDHSP575 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: Ā· Aggregated volume Ā· Price | Ā See 4c) above | ||||
e) | Date of the transaction | 25 May 2023 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Ā
Follow the stocks
